AstraZeneca PLC (LON:AZN) Receives £143.33 Average PT from Brokerages

Shares of AstraZeneca PLC (LON:AZN) have been assigned an average rating of “Moderate Buy” from the six analysts that are presently covering the company, MarketBeat reports. One analyst has rated the stock with a sell rating and five have assigned a buy rating to the company. The average 1-year target price among brokers that have updated their coverage on the stock in the last year is £145.83.

A number of equities research analysts have recently issued reports on the stock. Citigroup initiated coverage on shares of AstraZeneca in a report on Tuesday, January 27th. They issued a “buy” rating and a £170 target price on the stock. JPMorgan Chase & Co. restated an “overweight” rating on shares of AstraZeneca in a research note on Thursday, January 15th. Jefferies Financial Group reissued a “buy” rating and issued a £150 price objective on shares of AstraZeneca in a research report on Monday, November 10th. Deutsche Bank Aktiengesellschaft upped their price target on shares of AstraZeneca from £105 to £110 and gave the company a “sell” rating in a research note on Thursday, January 15th. Finally, Berenberg Bank upped their target price on AstraZeneca from £145 to £160 and gave the company a “buy” rating in a research report on Tuesday, January 27th.

AstraZeneca Price Performance

LON AZN opened at £136 on Tuesday. The stock has a market cap of £210.84 billion, a price-to-earnings ratio of 22.59, a PEG ratio of 0.86 and a beta of 0.17. The business has a 50 day simple moving average of £137.57 and a 200 day simple moving average of £126.01. The company has a debt-to-equity ratio of 73.83, a quick ratio of 0.59 and a current ratio of 0.93. AstraZeneca has a 52-week low of GBX 9,573.51 and a 52-week high of £144.10.

Insider Activity

In other AstraZeneca news, insider Nazneen Rahman sold 297 shares of AstraZeneca stock in a transaction dated Thursday, December 18th. The stock was sold at an average price of £134.96, for a total value of £40,083.12. Insiders own 0.14% of the company’s stock.

AstraZeneca Company Profile

AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas – Oncology, Cardiovascular, Renal & Metabolism, and Respiratory & Immunology.
Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on Twitter @AstraZeneca.